Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab Extension Study in SJIA and Hereditary Periodic Fevers
NCT02334748Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2014
- Primary completion
- Aug 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of canakinumab in systemic juvenile idiopathic arthritis (SJIA), Tumor necrosis factor receptor associated periodic syndrome (TRAPS), hyperimmunoglobulin D syndrome (HIDS), Familial Mediterranean fever (FMF), sponsored by Novartis. Started Nov 2014; status: completed.
02
Drugs
canakinumab
03
Conditions
systemic juvenile idiopathic arthritis (SJIA)Tumor necrosis factor receptor associated periodic syndrome (TRAPS)hyperimmunoglobulin D syndrome (HIDS)Familial Mediterranean fever (FMF)
Beyond the preview
Go deeper on NCT02334748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02334748.